Patents by Inventor David V. Schaffer

David V. Schaffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200085910
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Application
    Filed: May 29, 2019
    Publication date: March 19, 2020
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Publication number: 20200016233
    Abstract: Methods, pharmaceutical compositions, and kits are provided for treating a subject with an effective amount of an oxytocin receptor (OXTR) agonist and an effective amount of an ALK5 antagonist. In certain aspects, the OXTR agonist may be oxytocin or an oxytocin analog (e.g., a small molecule). The ALK 5 antagonist may be a small molecule, such as 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, LY2157299, A 83-01, D 4476, GW 788388, LY 364947, RepSox, SB 431542, SB 505124, SB 525334, or SD 208. In certain aspects, the amounts of the OXTR agonist and ALK5 antagonist may be sufficient to induce muscle regeneration and/or neural cell regeneration in the subject.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 16, 2020
    Inventors: Irina M. Conboy, David V. Schaffer, Hanadie Yousef, Michael J. Conboy, Wendy Cousin, Christian Elabd
  • Publication number: 20190382723
    Abstract: Methods and compositions for somatic cell proliferation as well as increasing viability of somatic cells are provided. The compositions include heparin binding protein isolated from a medium conditioned by growth of pluripotent stem cells, such as, human embryonic stem cells, human embryonic carcinoma cells. The methods include contacting a somatic cell with a heparin binding protein composition for a sufficient period of time to provide for enhanced proliferation and/or viability of the somatic cell as compared to the absence of the heparin binding protein composition.
    Type: Application
    Filed: January 14, 2019
    Publication date: December 19, 2019
    Inventors: Irina M. Conboy, Michael J. Conboy, Hanadie Yousef, David V. Schaffer
  • Patent number: 10494612
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery
  • Publication number: 20190218627
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 18, 2019
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Patent number: 10350267
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: July 16, 2019
    Assignee: the regents of the university of california
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Publication number: 20190169237
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 6, 2019
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Publication number: 20190117782
    Abstract: The instant disclosure provides cellularized hydrogels containing cells encapsulated in linked polymers of hyaluronic acid, heparin and other components as described herein. Such cellularized hydrogels find use in variety of purposes including effective transplantation of cells into a host organism for cell therapy and the derivation of desired cell types. Other purposes include but are not limited to use as a tissue model for the in vitro study of cellular responses and behaviors. The instant disclosure also provides methods, including methods of making and using the described cellularized hydrogels. Also provided are kits that include components for making and/or using cellularized hydrogels e.g., according to the methods as described herein.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 25, 2019
    Inventors: David V. Schaffer, Sanjay Kumar, Badriprasad Ananthanarayanan, Tandis Vazin, Maroof M. Adil
  • Patent number: 10214566
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provide methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Patent number: 10214785
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 10214725
    Abstract: Methods and compositions for somatic cell proliferation as well as increasing viability of somatic cells are provided. The compositions include heparin binding protein isolated from a medium conditioned by growth of pluripotent stem cells, such as, human embryonic stem cells, human embryonic carcinoma cells. The methods include contacting a somatic cell with a heparin binding protein composition for a sufficient period of time to provide for enhanced proliferation and/or viability of the somatic cell as compared to the absence of the heparin binding protein composition.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 26, 2019
    Assignee: The Regents of The University of California
    Inventors: Irina M. Conboy, Michael J. Conboy, Hanadie Yousef, David V. Schaffer
  • Patent number: 10202657
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20180325999
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Application
    Filed: February 20, 2018
    Publication date: November 15, 2018
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Publication number: 20180318431
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Application
    Filed: December 8, 2016
    Publication date: November 8, 2018
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Publication number: 20180289757
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 11, 2018
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Publication number: 20180251730
    Abstract: The present disclosure provides a three-dimensional culture system comprising a biocompatible polymer and a combination of factors in an amount effective to induce differentiation of oligodendrocyte precursors and/or oligodendrocytes from pluripotent stem cells. The present disclosure provides methods of generating oligodendrocyte precursors and/or oligodendrocytes using a three-dimensional culture system of the present disclosure. The present disclosure provides methods to treat neurological diseases and demyelinating diseases.
    Type: Application
    Filed: October 4, 2016
    Publication date: September 6, 2018
    Inventors: Gonçalo Rodrigues, David V. Schaffer
  • Publication number: 20180244859
    Abstract: The present disclosure provides thermoreversible polymers, hydrogel compositions comprising the thermoreversible polymers, as well as methods of making and using the thermoreversible polymers.
    Type: Application
    Filed: October 4, 2016
    Publication date: August 30, 2018
    Inventors: Christina Marie Fuentes, Barbara L. Ekerdt, David V. Schaffer, Rachel Segalman, Yuguo Lei
  • Patent number: 10046016
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: August 14, 2018
    Assignees: The Regents of the University of California, Integrative Gene Therapeutics
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Publication number: 20180155683
    Abstract: Methods and compositions for somatic cell proliferation as well as increasing viability of somatic cells are provided. The compositions include heparin binding protein isolated from a medium conditioned by growth of pluripotent stem cells, such as, human embryonic stem cells, human embryonic carcinoma cells. The methods include contacting a somatic cell with a heparin binding protein composition for a sufficient period of time to provide for enhanced proliferation and/or viability of the somatic cell as compared to the absence of the heparin binding protein composition.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 7, 2018
    Inventors: Irina M. Conboy, Michael J. Conboy, Hanadie Yousef, David V. Schaffer
  • Patent number: 9925237
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 27, 2018
    Assignee: The Regents of the University of California
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer